215 related articles for article (PubMed ID: 30033091)
1. MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation.
Jin L; Chun J; Pan C; Li D; Lin R; Alesi GN; Wang X; Kang HB; Song L; Wang D; Zhang G; Fan J; Boggon TJ; Zhou L; Kowalski J; Qu CK; Steuer CE; Chen GZ; Saba NF; Boise LH; Owonikoko TK; Khuri FR; Magliocca KR; Shin DM; Lonial S; Kang S
Cancer Cell; 2018 Aug; 34(2):315-330.e7. PubMed ID: 30033091
[TBL] [Abstract][Full Text] [Related]
2. Hsp90B enhances MAST1-mediated cisplatin resistance by protecting MAST1 from proteosomal degradation.
Pan C; Chun J; Li D; Boese AC; Li J; Kang J; Umano A; Jiang Y; Song L; Magliocca KR; Chen ZG; Saba NF; Shin DM; Owonikoko TK; Lonial S; Jin L; Kang S
J Clin Invest; 2019 Oct; 129(10):4110-4123. PubMed ID: 31449053
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin-mediated activation of glucocorticoid receptor induces platinum resistance via MAST1.
Pan C; Kang J; Hwang JS; Li J; Boese AC; Wang X; Yang L; Boggon TJ; Chen GZ; Saba NF; Shin DM; Magliocca KR; Jin L; Kang S
Nat Commun; 2021 Aug; 12(1):4960. PubMed ID: 34400618
[TBL] [Abstract][Full Text] [Related]
4. CRISPR/Cas9-based genome-wide screening for deubiquitinase subfamily identifies USP1 regulating MAST1-driven cisplatin-resistance in cancer cells.
Tyagi A; Kaushal K; Chandrasekaran AP; Sarodaya N; Das S; Park CH; Hong SH; Kim KS; Ramakrishna S
Theranostics; 2022; 12(13):5949-5970. PubMed ID: 35966591
[No Abstract] [Full Text] [Related]
5. USP28 promotes tumorigenesis and cisplatin resistance by deubiquitinating MAST1 protein in cancer cells.
Karapurkar JK; Colaco JC; Suresh B; Tyagi A; Woo SH; Jo WJ; Ko N; Singh V; Hong SH; Oh SJ; Kim KS; Ramakrishna S
Cell Mol Life Sci; 2024 Mar; 81(1):145. PubMed ID: 38498222
[TBL] [Abstract][Full Text] [Related]
6. Pulling a MAST1 on Cisplatin Resistance.
Jaykumar AB; Karra AS; Cobb MH
Cancer Cell; 2018 Aug; 34(2):183-185. PubMed ID: 30107173
[TBL] [Abstract][Full Text] [Related]
7. Extracellular ATP stimulates an inhibitory pathway towards growth factor-induced cRaf-1 and MEKK activation in astrocyte cultures.
Lenz G; Gonçalves D; Luo Z; Avruch J; Rodnight R; Neary JT
J Neurochem; 2001 May; 77(4):1001-9. PubMed ID: 11359865
[TBL] [Abstract][Full Text] [Related]
8. Induction of autophagy counteracts the anticancer effect of cisplatin in human esophageal cancer cells with acquired drug resistance.
Yu L; Gu C; Zhong D; Shi L; Kong Y; Zhou Z; Liu S
Cancer Lett; 2014 Dec; 355(1):34-45. PubMed ID: 25236911
[TBL] [Abstract][Full Text] [Related]
9. Modulation of Raf/MEK/ERK kinase activity does not affect the chemoresistance profile of advanced prostate cancer cells.
Lee JT; Steelman LS; McCubrey JA
Int J Oncol; 2005 Jun; 26(6):1637-44. PubMed ID: 15870880
[TBL] [Abstract][Full Text] [Related]
10. miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway.
Sun W; Ping W; Tian Y; Zou W; Liu J; Zu Y
Cell Physiol Biochem; 2018; 51(5):2160-2171. PubMed ID: 30522099
[TBL] [Abstract][Full Text] [Related]
11. Mast1 mediates radiation-induced gastric injury via the P38 MAPK pathway.
Ding W; Lu Y; Zhou A; Chen Y; Wang Z; Wang L; Tian Y
Exp Cell Res; 2021 Dec; 409(2):112913. PubMed ID: 34774870
[TBL] [Abstract][Full Text] [Related]
12. Microtubule affinity-regulating kinase 2 is associated with DNA damage response and cisplatin resistance in non-small cell lung cancer.
Hubaux R; Thu KL; Vucic EA; Pikor LA; Kung SH; Martinez VD; Mosslemi M; Becker-Santos DD; Gazdar AF; Lam S; Lam WL
Int J Cancer; 2015 Nov; 137(9):2072-82. PubMed ID: 25907283
[TBL] [Abstract][Full Text] [Related]
13. Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells.
Peng DJ; Wang J; Zhou JY; Wu GS
Biochem Biophys Res Commun; 2010 Apr; 394(3):600-5. PubMed ID: 20214883
[TBL] [Abstract][Full Text] [Related]
14. Tpl-2 induces IL-2 expression in T-cell lines by triggering multiple signaling pathways that activate NFAT and NF-kappaB.
Tsatsanis C; Patriotis C; Tsichlis PN
Oncogene; 1998 Nov; 17(20):2609-18. PubMed ID: 9840924
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
16. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.
Ahronian LG; Sennott EM; Van Allen EM; Wagle N; Kwak EL; Faris JE; Godfrey JT; Nishimura K; Lynch KD; Mermel CH; Lockerman EL; Kalsy A; Gurski JM; Bahl S; Anderka K; Green LM; Lennon NJ; Huynh TG; Mino-Kenudson M; Getz G; Dias-Santagata D; Iafrate AJ; Engelman JA; Garraway LA; Corcoran RB
Cancer Discov; 2015 Apr; 5(4):358-67. PubMed ID: 25673644
[TBL] [Abstract][Full Text] [Related]
17. PIM2 kinase is induced by cisplatin in ovarian cancer cells and limits drug efficacy.
Musiani D; Hammond DE; Cirillo L; Erriquez J; Olivero M; Clague MJ; Di Renzo MF
J Proteome Res; 2014 Nov; 13(11):4970-82. PubMed ID: 25099161
[TBL] [Abstract][Full Text] [Related]
18. Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway.
Lin CC; Yeh HH; Huang WL; Yan JJ; Lai WW; Su WP; Chen HH; Su WC
Am J Respir Cell Mol Biol; 2013 Aug; 49(2):241-50. PubMed ID: 23526220
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of the CRAF/prohibitin interaction reverses CRAF-dependent resistance to vemurafenib.
Doudican NA; Orlow SJ
Oncogene; 2017 Jan; 36(3):423-428. PubMed ID: 27321184
[TBL] [Abstract][Full Text] [Related]
20. Ras-mediated activation of ERK by cisplatin induces cell death independently of p53 in osteosarcoma and neuroblastoma cell lines.
Woessmann W; Chen X; Borkhardt A
Cancer Chemother Pharmacol; 2002 Nov; 50(5):397-404. PubMed ID: 12439598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
